DNDN: A risk. but a good buy

See my Dendreon 'analysis' for more accurate insight on the Provenge saga.

i believe your right. good analyst. thanks for your input. i will use it.
-rpmf08

I don't know if you've followed the entire story closely since it originally began... but if the drug is passed at the upcoming results review (expected in the 2nd half of this year) then you'll likely see the stock skyrocket more like to the $15 to $20 dollar rage rather quickly as suppose to going up a mere 40-80%. Although profits may not be realized right away some expect that provenge will be a billion dollar per year drug in the US alone and with the rights to full international production on their own, you could see it go even higher than that. They also have other products that they are working on which use the same immune therapy, such as Nuvenge for breast cancer, and if provenge ends up showing it can extend life with little side effects then don't be surprised if other immune therapy type of treatments make it to market as well. Now if the approval doesn't get done by second half of 2008 they will have a final review I believe next year in 2009 at which point they'll go through the rest of the data. But any rejection and this company will likely drop 50-80 plus percent. So only time will tell at this point IMHO.

Also, the company didn't turn it down simply because two panel members were in a conflict of interest - although that didn't help when they voted. I believe it was that the company didn't meet the endpoints which they were testing for in their earlier trials.

If you want to learn more about provenge you can visit a website that was setup for it by supporters at www.caretolive.com.